Circulating ceramide ratios and risk of vascular brain aging and dementia
Open Access
- 16 January 2020
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 7 (2) , 160-168
Abstract
Background: We determined the association between ratios of plasma ceramide species of differing fatty‐acyl chain lengths and incident dementia and Alzheimer’s disease (AD) dementia in a large, community‐based sample.Methods: We measured plasma ceramide levels in 1892 [54% women, mean age 70.1 (SD 6.9) yr.] dementia‐free Framingham Offspring Study cohort participants between 2005 and 2008. We related ratios of very long‐chain (C24:0, C22:0) to long‐chain (C16:0) ceramides to subsequent risk of incident dementia and AD dementia. Structural MRI brain measures were included as secondary outcomes.Results: During a median 6.5 year follow‐up, 81 participants developed dementia, of whom 60 were diagnosed with AD dementia. In multivariable Cox‐proportional hazards analyses, each standard deviation (SD) increment in the ratio of ceramides C24:0/C16:0 was associated with a 27% reduction in the risk of dementia (HR 0.73, 95% CI 0.56–0.96) and AD dementia (HR 0.73, 95% CI 0.53–1.00). The ratio of ceramides C22:0/C16:0 was also inversely associated with incident dementia (HR per SD 0.75, 95% CI 0.57–0.98), and approached statistical significance for AD (HR 0.73, 95% CI 0.53–1.01, P = 0.056). Higher ratios of ceramides C24:0/C16:0 and C22:0/C16:0 were also cross‐sectionally associated with lower white matter hyperintensity burden on MRI (−0.05 ± 0.02, P = 0.02; −0.06 ± 0.02, P = 0.003; respectively per SD increase), but not with other MRI brain measures.Conclusions: Higher plasma ratios of very long‐chain to long‐chain ceramides are associated with a reduced risk of incident dementia and AD dementia in our community‐based sample. Circulating ceramide ratios may serve as potential biomarkers for predicting dementia risk in cognitively healthy adults.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (N01‐HC‐25195, HHSN268201500001I, 75N92019D00031, R01 HL60040, R01 HL70100, P20 HL113444)
- National Institute on Aging (R01 AG054076, R01 AG049607, R01 AG033193, U01 AG049505, U01 AG052409)
- National Institute of Neurological Disorders and Stroke (NS017950, UH2 NS100605)
- National Heart Foundation of Australia
This publication has 43 references indexed in Scilit:
- Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegenerationThe Lancet Neurology, 2013
- Myeloid cell–specific serine palmitoyltransferase subunit 2 haploinsufficiency reduces murine atherosclerosisJournal of Clinical Investigation, 2013
- Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun LipidomicsPLOS ONE, 2011
- Serum sphingomyelins and ceramides are early predictors of memory impairmentNeurobiology of Aging, 2010
- Sphingolipids in inflammation: pathological implications and potential therapeutic targetsBritish Journal of Pharmacology, 2009
- Protection of C. elegans from Anoxia by HYL-2 Ceramide SynthaseScience, 2009
- Direct interaction between the inhibitor 2 and ceramide via sphingolipid‐protein binding is involved in the regulation of protein phosphatase 2A activity and signalingThe FASEB Journal, 2008
- Ceramide: A common pathway for atherosclerosis?Atherosclerosis, 2008
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- The framingham offspring study. Design and preliminary dataPreventive Medicine, 1975